Business
Voyageur Files Updated NI-43-101 Report on the Frances Creek Project & Completes SGS Canada Inc. Mine Site Visit for Advancement of PEA
(TheNewswire) Calgary, Alberta - TheNewswire - Novemb...
About this update from Voyageur Pharmaceuticals Ltd
[{"type":"text","content":"Voyageur Files Updated NI-43-101 Report on the Frances Creek Project & Completes SGS Canada Inc. Mine Site Visit for Advancement of PEA\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Calgary, Alberta -\n \n \n TheNewswire\n \n \n -\n \n \n November 2,\n \n \n 2020\n \n \n - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (the\n\"Company\" or \"Voyageur\") is pleased to announce\nthe filing of its updated Frances Creek (FC) NI 43-101 Technical\nReport on SEDAR. Voyageur is working with SGS Canada Inc. (SGS) to\ncomplete a Preliminary Economic Assessment (PEA) and Pre-Feasibility\n(PF) study on its FC barium contrast project. SGS completed its site\nvisit during the last week of October, 2020. This visit was a critical\nstep forward in order to complete the PEA/Pre - Feasibility by Q1\n2021.\n \n \n \n \n Voyageur is currently working with SGS on the testing\nof the barium concentrates produced by the TOMRA - COM XRT 300 sorting\nmachine. The sorting machine is intended to be used to create the\nfirst stage concentrated barite located at the quarry site. This\ntechnology will eliminate tailing ponds reduce water consumption and\nresult in a small environmental footprint.\n \n \n \n \n Voyageur continues to focus on creating cash flow using\nthird party minerals and manufacturing. Voyageur is working with third\nparties in Calgary and India who can manufacture the barium\nradio-graphic contrast media products. Voyageur's immediate milestones\nare to complete the PEA, PF, and initiate barium contrast sales with\nthird party manufacturers after receiving Health Canada approvals of\nits products. Upon completion of these milestones, Voyageur will move\nforward with the FC bulk sample project.\n \n \n \n \n About Voyageur\n \n \n \n \n Voyageur Pharmaceuticals Ltd. is a Canadian public\ncompany listed on the TSX Venture Exchange under the trading symbol\nVM. Voyageur is focused on the development of barite, iodine, and\nfullerene Active Pharmaceutical Ingredient (API) minerals. The\nnear-term focus is developing barium pharmaceutical products.\nVoyageur's goal is to initially generate positive cash flow from\noperations using third party GMP (Good Manufacturing Practices)\npharmaceutical manufacturers. Ultimately, Voyageur has plans to build\nall the required infrastructure to become 100% self-sufficient with\nall m...